Clinical characteristics comparing AIP-positive and AIP-negative patients
| Clinical characteristic | AIP positive | AIP negative | P value |
| Familial, n (%) | 89 (66.4) | 518 (40.8) | <0.001 |
| Gender, n (% male) | 83 (61.9) | 597 (47.1) | 0.001 |
| Diagnosis, n (%) | <0.001 | ||
| GH excess | 119 (88.8) | 648 (52) | |
| NFPA | 4 (3) | 181 (14.5) | |
| Prolactinoma | 11 (8.2) | 333 (26.7) | |
| Cushing’s disease | 0 | 74 (5.9) | |
| Other diagnosis | 0 | 11 (0.9) | |
| Age of onset (years and percentages) | <0.001 | ||
| 0–18 | 79 (60.3) | 259 (23.6) | |
| 19–30 | 33 (25.2) | 506 (46) | |
| >30 | 19 (14.5) | 336 (30.5) | |
| Age at diagnosis (years and percentages) | <0.001 | ||
| 0–18 | 53 (40.5) | 163 (14.1) | |
| 19–30 | 44 (33.6) | 497 (43) | |
| >30 | 34 (26) | 495 (42.9) | |
| Maximum diameter (mm)* | 16 (10.7–25) | 20 (11–30) | 0.518 |
| Macroadenoma, n (%) | 112 (93.3) | 865 (80.2) | <0.001 |
| Extrasellar extension, n (%) | 52 (81.3) | 394 (58.1) | <0.001 |
| Pituitary apoplexy, n (%) | 12 (9.5) | 36 (3.3) | 0.001 |
| Number of treatments* | 2 (1–3) | 1(1–2) | 0.055 |
↵*Median and IQR.
NFPA, non-functioning pituitary adenoma.